Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1981 to 1995 of 8801 results

  1. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Ravulizumab for treating primary IgA nephropathy [ID6703]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. DB-OTO for Hearing loss [ID6728]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

    Awaiting development Reference number: GID-TA11910 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication

    Awaiting development Reference number: GID-HTG10530 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care

    Awaiting development Reference number: GID-HTG10531 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  11. Point-of-care lipid tests for cardiovascular disease prevention in primary and community care

    Awaiting development Reference number: GID-HTG10528 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    In development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Excimer Laser Trabeculotomy (ELT) for glaucoma

    Awaiting development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date: TBC

    NICE guideline
    In development

  15. Obinutuzumab for treating primary membranous nephropathy [ID6751]

    Awaiting development Reference number: GID-TA11983 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development